Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors

The majority of patients with gastrointestinal stromal tumors (GIST) eventually become resistant with time due to secondary mutations in the driver receptor tyrosine kinase. Novel treatments that do not target these receptors may therefore be preferable. For the first time, we evaluated a tubulin in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yannick, Wozniak, Agnieszka, Wellens, Jasmien, Gebreyohannes, Yemarshet K., Guillén, Maria Jose, Avilés, Pablo M., Debiec-Rychter, Maria, Sciot, Raf, Schöffski, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381700/
https://www.ncbi.nlm.nih.gov/pubmed/32711367
http://dx.doi.org/10.1016/j.tranon.2020.100832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381700/
https://www.ncbi.nlm.nih.gov/pubmed/32711367
http://dx.doi.org/10.1016/j.tranon.2020.100832

Ejemplares similares